Regardless of the sequential decrease in Current Liabilities, during the second quarter 2024, Quick Ratio deteriorated to 7.3 below Talis Biomedical's average Quick Ratio.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Quick Ratio than Talis Biomedical in second quarter 2024. While Quick Ratio total ranking has improved so far during the Q2 2024 to 393, from total ranking in the first quarter 2024 at 404.

Explain Quick Ratio?
How much Cash & cash equivalents TLIS�s has?
What are TLIS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TLIS Quick Ratio	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3	(Jun 30 2023) Q2
Y / Y Current Liabilities Change	-11.51 %	-15.29 %	-30.78 %	-25.73 %	-33.38 %
Y / Y Cash & cash equivalent Change	-39.04 %	-37.73 %	-41.06 %	-38.8 %	-40.62 %
Quick Ratio MRQ	7.3	7.43	8.75	10.41	10.6
TLIS's Total Ranking	# 393	# 404	# 372	# 314	# 238
Seq. Current Liabilities Change	-13.46 %	7.97 %	3.81 %	-8.77 %	-17.16 %
Seq. Cash & cash equivalent Change	-14.89 %	-8.33 %	-12.8 %	-10.39 %	-13.07 %

Quick Ratio second quarter 2024 Company Ranking
Within:	No.
Laboratory Analytical Instruments Industry	# 6
Healthcare Sector	# 210
Overall Market	# 393

Quick Ratio Statistics
High	Average	Low
32.15	11.36	4.32
(Mar 31 2021)		(Jun 30 2021)

Financial Statements
Talis Biomedical's Current Liabilities	$ 8 Millions	Visit TLIS's Balance sheet
Talis Biomedical's Cash & cash equivalent	$ 60 Millions	Visit TLIS's Balance sheet
Source of TLIS's Sales		Visit TLIS's Sales by Geography

Cumulative Talis Biomedical's Quick Ratio

TLIS's Quick Ratio for the trailling 12 Months

TLIS Quick Ratio	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	-21.58 %	-26.82 %	-29.24 %	-30.34 %	-44.12 %
Y / Y Cash & cash equivalent TTM Growth	-39.21 %	-39.66 %	-40.04 %	-41.13 %	-43.53 %
Quick Ratio TTM	8.45	9.27	9.98	10.33	10.9
Total Ranking TTM	# 3046	# 3003	# 2990	# 3210	# 2838
Seq. Current Liabilities TTM Growth	-2.96 %	-4.54 %	-9.38 %	-6.58 %	-9.45 %
Seq. Cash & cash equivalent TTM Growth	-11.5 %	-11.34 %	-12.45 %	-11.5 %	-12.16 %

Quick ratio ranking by company, industry and sector >> Back to TLIS Financial Strength Comparisons >> Go to Compare TLIS Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in TLIS's Current Liabilities to $8.20 millions, cumulative Quick Ratio to 8.45 below the TLIS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Laboratory Analytical Instruments industry 23 other companies have achieved higher Quick Ratio than Talis Biomedical. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 3003 to 3046.

Explain Quick Ratio?
How much Cash & cash equivalents TLIS�s has?
What are TLIS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Laboratory Analytical Instruments Industry	# 24
Healthcare Sector	# 892
Within the Market	# 3046

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.22	9.92	6.87
(Sep 30 2022)		(Dec 31 2021)

Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Laboratory Analytical Instruments Industry	Quick Ratio	Jun 30 2024 MRQ Cash & cash equivalent	Jun 30 2024 MRQ Current Liabilities
Nautilus Biotechnology Inc	19.29	$ 167.443 Millions	$ 8.681 Millions
Seer Inc	16.64	$ 283.453 Millions	$ 17.037 Millions
Singular Genomics Systems Inc	13.48	$ 133.204 Millions	$ 9.882 Millions
Astrotech Corp	12.63	$ 31.916 Millions	$ 2.528 Millions
10x Genomics Inc	10.42	$ 380.096 Millions	$ 36.494 Millions
Pacific Biosciences Of California Inc	8.58	$ 509.802 Millions	$ 59.396 Millions
Rapid Micro Biosystems Inc	7.46	$ 69.390 Millions	$ 9.300 Millions
Talis Biomedical Corporation	7.30	$ 59.867 Millions	$ 8.196 Millions
Quanterix Corporation	7.04	$ 296.855 Millions	$ 42.166 Millions
Cytek Biosciences Inc	5.29	$ 277.211 Millions	$ 52.379 Millions
Reflect Scientific Inc	5.10	$ 1.103 Millions	$ 0.216 Millions
Bio rad Laboratories Inc	5.06	$ 1,621.666 Millions	$ 320.788 Millions
Eyepoint Inc	4.64	$ 288.248 Millions	$ 62.102 Millions
Standard Biotools Inc	3.19	$ 394.713 Millions	$ 123.808 Millions
Waters Corporation	1.47	$ 327.934 Millions	$ 223.138 Millions

Date modified: 2026-08-29T17:43:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.